IRIS
UCCELLI, ANTONIO
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
EU - Europa 36.184
AS - Asia 255
SA - Sud America 48
NA - Nord America 6
AF - Africa 2
Totale 36.495
Salva come PNG Salva come JPEG
Nazione #
IT - Italia 36.179
CN - Cina 173
SG - Singapore 61
BR - Brasile 41
VN - Vietnam 17
US - Stati Uniti d'America 5
AR - Argentina 4
BE - Belgio 2
CO - Colombia 1
DE - Germania 1
EC - Ecuador 1
HK - Hong Kong 1
ID - Indonesia 1
IL - Israele 1
KE - Kenya 1
KZ - Kazakistan 1
MX - Messico 1
PE - Perù 1
RU - Federazione Russa 1
SE - Svezia 1
ZA - Sudafrica 1
Totale 36.495
Salva come PNG Salva come JPEG
Città #
Genova 19.862
Genoa 10.778
Rapallo 2.878
Vado Ligure 2.571
Bordighera 86
Beijing 81
Singapore 14
Ho Chi Minh City 8
São Paulo 7
Ashburn 4
Hanoi 4
Brussels 2
Curitiba 2
Taboão da Serra 2
Americana 1
Ananindeua 1
Arequipa 1
Belo Horizonte 1
Bonito 1
Brooklyn 1
Campos dos Goytacazes 1
Catende 1
Conceição do Jacuípe 1
Concordia 1
Contagem 1
Cà Mau 1
Daule 1
Frankfurt am Main 1
Goiânia 1
Gramado 1
Guangzhou 1
Guarapuava 1
Guaíba 1
Gustavo Adolfo Madero 1
Hong Kong 1
Hải Dương 1
Iguape 1
Itatiba 1
Jardín América 1
Ji Paraná 1
Juiz de Fora 1
Kovrov 1
Long An 1
Medan 1
Milan 1
Nairobi 1
Natal 1
Na‘an 1
Ninh Bình 1
Nova Serrana 1
Novo Hamburgo 1
Papanduva 1
Petrolina 1
Popayán 1
Recife 1
Reconquista 1
Registro 1
Rome 1
Salvador 1
San Miguel del Monte 1
Santa Cruz Cabrália 1
Serra 1
Shymkent 1
Sorocaba 1
Stellenbosch 1
Terra Nova 1
Thái Bình 1
Tianjin 1
Uppsala 1
Vitória 1
Várzea Paulista 1
Totale 36.356
Salva come PNG Salva come JPEG
Nome #
C-C chemokine receptor 6-regulated entry of TH-17 cells into the CNS through the choroid plexus is required for the initiation of EAE. 242
Composite MRI measures and short-term disability in patients with clinically isolated syndrome suggestive of MS 227
Safety and tolerability of fingolimod in patients with relapsing-remitting multiple sclerosis: results of an open-label clinical trial in Italy 222
Finger motor performance as a new quantitative clinical endpoint in multiple sclerosis 218
Multipotent mesenchymal stromal cells from amniotic fluid: solid perspectives for clinical application. 209
Adult stem cells for spinal cord injury: what types and how do they work? 208
17p11.2 duplication is a common finding in sporadic cases of charcot-marie-tooth type 1 205
Association of melanoma and natalizumab therapy in the Italian MS population: a second case report. 195
Blood-Brain Barrier Alterations in the Cerebral Cortex in Experimental Autoimmune Encephalomyelitis. 195
Neuroprotective features of mesenchymal stem cells. 193
Mesenchymal stem cells ameliorate experimental autoimmune encephalomyelitis inducing T-cell anergy. 188
CCL5-glutamate interaction in central nervous system: Early and acute presynaptic defects in EAE mice 188
Alpha-lipoic acid is effective in prevention and treatment of experimental autoimmune encephalomyelitis. 188
Early switch to fingolimod may decrease the risk of disease recurrence after natalizumab interruption 184
Catastrophic NAD(+) Depletion in Activated T Lymphocytes through Nampt Inhibition Reduces Demyelination and Disability in EAE 183
Unveiling the enigma of the CNS as a B-cell fostering environment. 180
IFN-γ orchestrates mesenchymal stem cell plasticity through the signal transducer and activator of transcription 1 and 3 and mammalian target of rapamycin pathways 180
Mesenchymal stem cells effectively modulate pathogenic immune response in experimental autoimmune encephalomyelitis. 176
Hereditary motor and sensory neuropathy with myelin outfolding: clinical, genetic and neuropathological study of three cases 176
Quantitative 3D investigation of Neuronal network in mouse spinal cord model 175
Immunotherapy for neurological diseases. 175
A restricted T cell response to myelin basic protein (MBP) is stable in multiple sclerosis (MS) patients. 174
Urinary JCV-DNA Testing during Natalizumab Treatment May Increase Accuracy of PML Risk Stratification. 172
Mechanisms of the adaptive immune response inside the central nervous system during inflammatory and autoimmune diseases. 171
Regulation of human mesenchymal stem cell functions by an autocrine loop involving NAD+ release and P2Y11-mediated signaling. 171
Human mesenchymal stem cells target adhesion molecules and receptors involved in T cell extravasation 171
Different MRI patterns in MS worsening after stopping fingolimod 171
Sirt6 regulates dendritic cell differentiation, maturation, and function 170
Can we switch microglia's phenotype to foster neuroprotection? Focus on multiple sclerosis. 169
Conversion from clinically isolated syndrome to multiple sclerosis: A large multicentre study. 169
Autologous haematopoietic stem cell transplantation with an intermediate intensity conditioning regimen in multiple sclerosis: the Italian multi-centre experience. 169
Charcot-Marie-Tooth (CMT) 1a duplication at 17p11.2 in Italian families. 168
Recapitulation of B cell differentiation in the central nervous system of patients with multiple sclerosis. 168
In vitro VLA-4 blockade results in an impaired NK cell-mediated immune surveillance against melanoma 166
The molecular signature of therapeutic mesenchymal stem cells exposes the architecture of the hematopoietic stem cell niche synapse. 166
Investigation of paroxysmal dystonia in a patient with multiple sclerosis: a transcranial magnetic stimulation study. 165
Interferon-γ-dependent inhibition of B cell activation by bone marrow-derived mesenchymal stem cells in a murine model of systemic lupus erythematosus. 164
A major influence of the T cell receptor repertoire as compared to antigen processing-presentation in the selection of myelin basic protein epitopes in multiple sclerosis. 163
Effect of radial shock wave therapy on pain and muscle hypertonia: a double-blind study in patients with multiple sclerosis. 163
The long-term effect of AHSCT on MRI measures of MS evolution: a five-year follow-up study. 163
Multipotent mesenchymal stromal cells for autoimmune diseases: teaching new dogs old tricks. 162
Nicotinamide Phosphoribosyltransferase (Nampt) Inhibitors As Therapeutics: Rationales, Controversies, Clinical Experience. 161
Exploring Alzheimer's disease mouse brain through X-ray phase contrast tomography: From the cell to the organ 161
Neurorepair with mesenchymal stem cells: hope or hype? 160
Autologous stem cell transplantation as rescue therapy in malignant forms of multiple sclerosis. 160
A RCT Comparing Specific Intensive Cognitive Training to Aspecific Psychological Intervention in RRMS: The SMICT Study 160
Retinal nerve fibre layer measurements and optic nerve head analysis in multiple sclerosis patients. 159
Antibodies against Epstein-Barr virus and herpesvirus type 6 are associated with the early phases of multiple sclerosis. 159
Alterations of glutamate release in the spinal cord of mice with experimental autoimmune encephalomyelitis 159
Intense immunosuppression followed by autologous stem cell transplantation in severe multiple sclerosis. 158
Low intensity lympho-ablative regimen followed by autologous hematopoietic stem cell transplantation in severe forms of multiple sclerosis: A MRI-based clinical study. 157
Immuno-therapeutic potential of haematopoietic and mesenchymal stem cell transplantation in MS. 157
Anti-Glutamic Acid Decarboxylase Limbic Encephalitis Without Epilepsy Evolving Into Dementia With Cerebellar Ataxia 157
Dysregulation of regulatory CD56bright NK cells/T cells interactions in multiple sclerosis 156
Demyelination and axonal damage in a non-human primate model of multiple sclerosis. 155
Acute desipramine restores presynaptic cortical defects in murine experimental autoimmune encephalomyelitis by suppressing central CCL5 overproduction. 154
Autologous hematopoietic stem cell transplantation in multiple sclerosis: A phase II trial. 154
Sirt6 inhibition delays the onset of experimental autoimmune encephalomyelitis by reducing dendritic cell migration 154
Analisi e studio longitudinale della fine specificità di linee linfocitarie T specifiche per la proteina basica della mielina (MBP) in pazienti con sclerosi multipla e in controlli normali. 153
Autologous haematopoietic stem-cell transplantation in multiple sclerosis: benefits and risks 152
Autologous stem cell transplantation for severe autoimmune diseases: a 10-year experience. 152
Relapses after treatment with rituximab in a patient with multiple sclerosis and anti myelin-associated glycoprotein polyneuropathy. 152
X-Ray Phase Contrast Tomography Reveals Early Vascular Alterations and Neuronal Loss in a Multiple Sclerosis Model 152
Mesenchymal stem cells shape microglia effector functions through the release of CX3CL1 151
The therapeutic effect of mesenchymal stem cell transplantation in experimental autoimmune encephalomyelitis is mediated by peripheral and central mechanisms 151
Primary varicella zoster infection associated with fingolimod treatment. 150
Characterization of mouse spinal cord vascular network by means of synchrotron radiation X-ray phase contrast tomography 150
Relationship between retinal inner nuclear layer, age, and disease activity in progressive MS 150
Ghost spasticity in multiple sclerosis 150
Reciprocal interactions between human mesenchymal stem cells and gammadelta T cells or invariant natural killer T cells. 149
NG2, a common denominator for neuroinflammation, blood-brain barrier alteration, and oligodendrocyte precursor response in EAE, plays a role in dendritic cell activation 149
Human mesenchymal stem cells promote survival of T cells in a quiescent state. 149
Why should mesenchymal stem cells (MSCs) cure autoimmune diseases? 148
Mesenchymal stem cells for multiple sclerosis: does neural differentiation really matter? 147
Cingulum bundle alterations underlie subjective fatigue in multiple sclerosis 146
Phenotypic and functional characterisation of CCR7+ and CCR7- CD4+ memory T cells homing to the joints in juvenile idiopathic arthritis. 146
Mesenchymal stem cells impair in vivo T-cell priming by dendritic cells. 146
The therapeutic potential of mesenchymal stem cell transplantation as a treatment for multiple sclerosis: consensus report of the International MSCT Study Group. 145
Dramatic rebounds of MS during pregnancy following fingolimod withdrawal. 145
Stem cells for multiple sclerosis: promises and reality. 144
A case of thyroiditis during natalizumab therapy for multiple sclerosis 144
Intrathecal soluble HLA-E correlates with disease activity in patients with multiple sclerosis and may cooperate with soluble HLA-G in the resolution of neuroinflammation. 143
Immunological patterns identifying disease course and evolution in multiple sclerosis patients. 143
T-cell trafficking in the central nervous system. 142
Teriflunomide treatment reduces B cells in patients with MS. 141
Central and peripheral nervous system complications following allogeneic bone marrow transplantation. 141
Selective impairments of motor sequence learning in multiple sclerosis patients with minimal disability 140
Fingolimod Modulates Peripheral Effector and Regulatory T Cells in MS Patients. 140
Neuroprotective mesenchymal stem cells are endowed with a potent antioxidant effect in vivo. 140
Safety of the first dose of fingolimod for multiple sclerosis: results of an open-label clinical trial. 139
Clinical baseline factors predict response to natalizumab: their usefulness in patient selection. 138
CSF oligoclonal bands and normal appearing white matter periventricular damage in patients with clinically isolated syndrome suggestive of MS 138
Degree of microstructural changes within T1-SE versus T1-GE hypointense lesions in multiple sclerosis: relevance for the definition of “black holes” 138
Mesenchymal stem cells for the treatment of multiple sclerosis and other neurological diseases 137
Conventional perimetry, short-wavelength automated perimetry, frequency-doubling technology, and visual evoked potentials in the assessment of patients with multiple sclerosis. 137
Quantitative assessment of finger motor impairment in multiple sclerosis. 136
Fumarates modulate microglia activation through a novel HCAR2 signaling pathway and rescue synaptic dysregulation in inflamed CNS 136
A bridge between evidence-based laboratory diagnostics and research in neuroimmunology: why standardizations and guidelines matter. 136
Hypothalamic AgRP neurons control hematopoiesis and lymphopoiesis and are activated in experimental MS 134
Interindividual variability of cranioencephalic relationships as predicted by CT. 134
Totale 16.197
Salva come PNG Salva come JPEG
Categoria #
all - tutte 126.594
article - articoli 111.756
book - libri 425
conference - conferenze 10.545
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 3.868
Totale 253.188
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2020/20211.772 0 0 0 221 147 200 149 230 193 291 169 172
2021/20223.469 107 213 319 457 152 193 143 755 174 317 118 521
2022/20233.468 329 292 41 362 558 581 21 221 593 37 362 71
2023/20242.391 110 246 70 274 181 405 239 158 126 71 147 364
2024/20257.029 339 480 212 467 811 685 729 1.261 296 361 612 776
2025/20263.919 1.617 428 800 1.074 0 0 0 0 0 0 0 0
Totale 37.179